Search

Nemiralisib

Nemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary

Nirogacestat

Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a

2'-fluoro-5-ethylarabinosyluracil

2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma

KC706

KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.

Lofentanil

Lofentanil is an analog of fentanyl and is one of the most potent opioids available today.

ATN-161

expected to extend to a variety of cancers. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.

CX516

CMLVAX100

CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.

Cilnidipine

Cilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

Cefacetrile

A derivative of 7-aminocephalosporanic acid.